26 results on '"Gladman, Dafna D"'
Search Results
2. Updates on Axial Psoriatic Arthritis From the 2020 GRAPPA Annual Meeting.
- Author
-
Gladman, Dafna D., Helliwell, Philip S., Poddubnyy, Denis, and Mease, Philip J.
- Subjects
PSORIATIC arthritis ,PSORIASIS ,ARTHRITIS - Abstract
This article summarizes sessions that dealt with axial psoriatic arthritis (axPsA) at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2020 virtual meeting. The summary includes the symposium, which comprised a plenary presentation by Dr. Dafna Gladman from Toronto, Canada, as well as a panel discussion with Dr. Philip Helliwell, Dr. Denis Poddubnyy, and Dr. Gladman, moderated by Dr. Philip Mease. In addition, the paper also summarizes Dr. Mease's "Meet the Expert" session, which focused on axPsA. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. GRAPPA 2019 Project Report.
- Author
-
Goel, Niti, Coates, Laura C., De Marco, Gabriele, Eder, Lihi, FitzGerald, Oliver, Helliwell, Philip S., Ying Ying Leung, Maksymowych, Walter P., Mease, Philip J., Østergaard, Mikkel, O'Sullivan, Denis, Poddubnyy, Denis, Ritchlin, Christopher T., and Gladman, Dafna D.
- Subjects
PSORIASIS ,PSORIATIC arthritis ,EDUCATION research ,RESEARCH grants ,MAGNETIC resonance imaging - Abstract
At the 2019 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members received updates on several ongoing efforts. Among them were updates on research, including the trainee symposium, pilot research grants, and the Collaborative Research Network; GRAPPA's patient research partners; education, including the slide collection; treatment recommendations; and additional work related to advancing the understanding of disease aspects, including the Outcome Measures in Rheumatology (OMERACT)-GRAPPA outcome measure, axial involvement, and ultrasound enthesitis projects; as well as the early psoriatic disease systematic literature review and magnetic resonance imaging. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. The GRAPPA-OMERACT Working Group: 4 Prioritized Domains for Completing the Core Outcome Measurement Set for Psoriatic Arthritis 2019 Updates.
- Author
-
Ying Ying Leung, Tillett, William, Orbai, Ana-Maria, Ogdie, Alexis, Eder, Lihi, Coates, Laura C., Holland, Richard, Antony, Anna, Goel, Niti, Mease, Philip J., Strand, Vibeke, FitzGerald, Oliver, de Wit, Maarten, Lindsay, Christine A., Duffin, Kristina Callis, and Gladman, Dafna D.
- Subjects
PSORIASIS ,PSORIATIC arthritis ,MUSCULOSKELETAL system diseases ,FATIGUE (Physiology) ,RHEUMATOLOGY - Abstract
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)--Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) working group provided updates at the 2019 GRAPPA annual meeting on its work toward developing a core outcome set for PsA. The working group prioritized 4 domains, including musculoskeletal disease activity (enthesitis and dactylitis), fatigue, physical function, and structural damage. In this report, the working group summarizes its progress in standardizing the core outcome set for these 4 domains. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Outcomes of the 2019 GRAPPA Workshop on Continuous Composite Indices for the Assessment of Psoriatic Arthritis and Membership-recommended Next Steps.
- Author
-
Tillett, William, McHugh, Neil, Orbai, Ana-Maria, Ogdie, Alexis, Ying Ying Leung, Coates, Laura C., Mease, Philip J., Gladman, Dafna D., Brooke, Mel, Packham, Jon, O'Sullivan, Denis, FitzGerald, Oliver, and Helliwell, Philip S.
- Subjects
PSORIATIC arthritis ,PSORIASIS ,RHEUMATOLOGISTS ,DERMATOLOGISTS ,SKIN diseases - Abstract
Objective. Improving the assessment of psoriatic arthritis (PsA) is a key purpose of the Group for Research and Assessment of Psoriasis and PsA (GRAPPA). Herein, we report the proceedings of the GRAPPA composites workshop at the 2019 GRAPPA annual meeting and the membership's recommended next steps. Methods. A review of continuous composite measures was conducted in an introductory workshop, followed by 10 breakout group sessions and a final plenary session for feedback and voting. Results. Participants included 154 members: 87 rheumatologists, 18 dermatologists, 2 rheumatologist/ dermatologists, 12 patient research partners, 14 academics, 1 methodologist, and 20 industry members. Of voting members, 88.8% agreed a need exists for a continuous composite measure for routine practice, but only 62% were currently using a composite measure. Of these, 27% were using the 28-joint count Disease Activity Score (DAS), which is not a PsA-specific measure; 20% were using a PsA-specific measure such as PsA DAS (PASDAS), Composite Psoriatic Disease Activity Index (CPDAI), or Disease Activity Index for PsA (DAPSA). Members agreed that the existing measures were not feasible in their current forms (CPDAI 83%, PASDAS 82%, and DAPSA 47%) and that modification should be tested. The majority (76%) agreed that disease effect should be measured separately from disease activity. Conclusion. The GRAPPA membership supports the need for a continuous composite measure of disease activity for use in routine clinical care, the separate measurement of disease effect and activity, and the testing of modifications to candidate instruments rather than the development of new measures. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group
- Author
-
Leung, Ying Ying, Orbai, Ana-Maria, Tillett, William, Ogdie, Alexis, Eder, Lihi, Goel, Niti, Hojgaard, Pil, Holland, Richard, Mathew, Ashish J., Lindsay, Christine A., Antony, Anna, Chau, Jeffrey, Christensen, Robin, Coates, Laura C., Mease, Philip J., Strand, Vibeke, FitzGerald, Oliver, de Wit, Maarten, Duffin, Kristina Callis, and Gladman, Dafna D.
- Abstract
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Working Group provided updates at the 2020 GRAPPA annual meeting on its work toward developing a core outcome set for PsA. Working groups were set up for the 4 prioritized domains: enthesitis, fatigue, structural damage, and physical function. Two instruments for measurement of physical function were provisionally endorsed: (1) the Health Assessment Questionnaire-Disability Index and (2) the physical functioning domain in the Medical Outcomes Study 36-item Short Form survey.
- Published
- 2021
- Full Text
- View/download PDF
7. Prologue: 2020 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
- Author
-
Duffin, Kristina Callis, Gottlieb, Alice B., O'Sullivan, Denis, Gladman, Dafna D., and McFarland, Lynne V.
- Subjects
PSORIASIS treatment ,SKIN diseases ,CORONAVIRUS diseases ,RHEUMATOLOGISTS ,MEDICAL care - Abstract
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) held its annual meeting in 2020 in an online format due to travel restrictions during the coronavirus disease 2019 (COVID-19; caused by SARS-CoV-2) pandemic. The virtual meeting was attended by 351 rheumatologists, dermatologists, representatives of biopharmaceutical companies, and patient research partners. Similar to previous years, GRAPPA's annual meeting focused on the 3 overlapping missions of education, research, and clinical care of psoriatic disease. Trainee sessions this year included the annual trainee symposium and a grant-writing workshop. Plenary sessions included updates on COVID-19 and psoriatic disease from multispecialty and patient perspectives, and updates on pustular psoriasis and associated musculoskeletal manifestations. Progress on research and updates were presented for the following groups: Collaborative Research Network, Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis Working Group, International Dermatology Outcome Measures, Composite Measures, Education Committee, and Treatment Guidelines. New this year were 3 concurrent workshops on ultrasound assessment of joints and entheses, magnetic resonance imaging of psoriatic arthritis, and pustular psoriasis efficacy endpoints; 6 "Meet the Expert" sessions; and facilitated "poster tours." In our prologue, we introduce the papers that summarize this meeting. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. The GRAPPA-OMERACT Working Group: 4 Prioritized Domains for Completing the Core Outcome Measurement Set for Psoriatic Arthritis 2019 Updates
- Author
-
Leung, Ying Ying, Tillett, William, Orbai, Ana-Maria, Ogdie, Alexis, Eder, Lihi, Coates, Laura C., Holland, Richard, Antony, Anna, Goel, Niti, Mease, Philip J., Strand, Vibeke, FitzGerald, Oliver, de Wit, Maarten, Lindsay, Christine A., Callis Duffin, Kristina, and Gladman, Dafna D.
- Abstract
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)–Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) working group provided updates at the 2019 GRAPPA annual meeting on its work toward developing a core outcome set for PsA. The working group prioritized 4 domains, including musculoskeletal disease activity (enthesitis and dactylitis), fatigue, physical function, and structural damage. In this report, the working group summarizes its progress in standardizing the core outcome set for these 4 domains.
- Published
- 2020
- Full Text
- View/download PDF
9. GRAPPA 2018 Project Report.
- Author
-
Goel, Niti, FitzGerald, Oliver, Gladman, Dafna D., Helliwell, Philip S., Kavanaugh, Arthur, Maksymowych, Walter P., Mease, Philip J., Ritchlin, Christopher T., and Coate, Laura C.
- Subjects
PSORIASIS ,PSORIATIC arthritis ,COOPERATIVE research ,RESEARCH grants ,PILOT projects - Abstract
At the 2018 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members received updates on several ongoing efforts. Among them were updates on GRAPPA's patient research partners; educational initiatives; research efforts, including the trainee symposium, pilot research grants, and Collaborative Research Network; treatment recommendations; and additional efforts related to advancing the understanding of disease aspects. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set.
- Author
-
Ying Ying Leung, Ana-Maria Orbai, Ogdie, Alexis, Coates, Laura C., de Wit, Maarten, Duffin, Kristina Callis, Eder, Lihi, Gladman, Dafna D., Goel, Niti, Mease, Philip J., Strand, Vibeke, FitzGerald, Oliver, and Tillett, William
- Subjects
PSORIATIC arthritis ,HEALTH outcome assessment ,MEDICAL needs assessment ,QUALITY of life ,RANDOMIZED controlled trials - Abstract
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Working Group reported at the 2018 GRAPPA annual meeting on the outcome of the OMERACT 2018 Conference in Terrigal, Australia. The working group presented the endorsement of the 66/68 joint count for the assessment of peripheral arthritis and the provisional endorsement of the PsA Impact of Disease 12 questionnaire for the assessment of PsA-specific health-related quality of life in PsA randomized controlled trials and observational studies. In this report, the group presents its plan to seek OMERACT endorsement for outcome measures that address the domains of MSK disease activity for enthesitis and dactylitis, physical function, fatigue, and structural damage following the OMERACT Filter 2.1 methodology. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
11. Best-practice Indicators in Psoriatic Disease Care.
- Author
-
Helliwell, Philip S., Favier, Guillaume, Gladman, Dafna D., Soriano, Enrique R., Kirkham, Bruce W., Coates, Laura C., Puig, Luis, Boehncke, Wolf-Henning, and Thaçi, Diamant
- Subjects
PSORIASIS ,PSORIATIC arthritis ,HEALTH status indicators ,HEALTH outcome assessment ,MEDICAL care standards - Abstract
Objective. In 2016, members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), in collaboration with KPMG LLP (UK), conducted a study to measure care in psoriatic arthritis (PsA). A key finding was that centers do not usually have processes in place to measure the effect of improved quality of care. Our objectives were to identify and select best-practice indicators to enable PsA caregivers to assess and monitor the outcomes of specific initiatives aimed at improving care in 4 focus areas: (1) shortening time to diagnosis; (2) improving multidisciplinary collaboration; (3) optimizing disease management; and (4) improving disease monitoring. Methods. (1) Structured review of scientific and grey literature to obtain evidence for a long list of 100 potential indicators across the 4 focus areas; (2) survey expert rheumatologists and dermatologists to review the long list and identify the most meaningful and feasible indicators for use in day-to-day practice; (3) consensus discussion to identify a shortlist of indicators based on predefined selection criteria; (4) electronic group discussion to refine definitions of shortlisted indicators and targets; and (5) review of the shortlisted indicators at the annual GRAPPA meeting in July 2018 to ensure the indicators meet the preliminary criteria. Results. The expert group arrived at a consensus with a shortlist of 8 best-practice indicators across 4 key focus areas aligned with the patient pathway. Conclusion. There were 8 evidence-based best-practice indicators and respective targets that were identified to enable the monitoring of quality of care and target improvements. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
12. Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting.
- Author
-
Jadon, Deepak R., Chandran, Vinod, Ogdie, Alexis, Pennington, Stephen R., Stober, Carmel, Gladman, Dafna D., de Wit, Maarten, O'Sullivan, Denis, Mease, Philip, Armstrong, April W., Duffin, Kristina Callis, Magee, Conor, Helliwell, Philip, Ritchlin, Christopher T., and FitzGerald, Oliver
- Subjects
COOPERATIVE research ,PILOT projects ,PSORIATIC arthritis ,BIOMARKERS ,HEALTH outcome assessment - Abstract
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Collaborative Research Network (CRN) intends to launch and secure funding for 3 pilot projects related to psoriatic disease, psoriatic arthritis (PsA), and cutaneous psoriasis (PsC). The first pilot project, a PsA Biomarkers for Joint Damage (BioDAM) pilot, will seek to determine the independent predictive ability of serum biomarkers for joint damage in PsA. The second pilot project will aim to identify predictors of the development of PsA among patients with PsC. The third pilot project will aim to identify biomarkers that predict treatment response in PsA and PsC. These pilot projects will prompt the development of clinical protocols to operate across participating centers, lead to the development of standard operating procedures for the collection and transport of biosamples across international borders, and begin to establish administrative and managerial structures for the CRN. The CRN hopes that the successful completion and research outputs of these 3 pilot projects will demonstrate the CRN's value to prospective collaborators and sponsors and thereby secure sustainable longterm funding. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
13. Prologue: 2019 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
- Author
-
Duffin, Kristina Callis, Gladman, Dafna D., Goel, Niti, and Gottlieb, Alice B.
- Subjects
PSORIASIS ,PSORIATIC arthritis ,RHEUMATOLOGISTS ,DERMATOLOGISTS ,SKIN diseases - Abstract
The 2019 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held in Paris, France, and was attended by rheumatologists, dermatologists, representatives of biopharmaceutical companies, and patients. As in previous years, GRAPPA members held a symposium for trainees to discuss their research in psoriatic disease with experts in the field. Other subjects featured during the annual meeting included a composites workshop to review continuous composite measures; the GRAPPA-Collaborative Research Network's third annual meeting; the need for a precision medicine approach to the treatment of psoriatic disease; updates from working groups in International Dermatology Outcome Measures and Outcome Measures in Rheumatology; a debate on the effectiveness of methotrexate in the treatment of psoriatic arthritis (PsA); updating recommendations for optimal treatment approaches for patients with PsA; an update on GRAPPA's research and educational projects; and the GRAPPA ultrasound (US) working group's goal to optimize the evaluation of enthesitis in patients with PsA using US through the development of a diagnostic US enthesitis tool. In this Prologue, we introduce the papers that summarize that meeting. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set
- Author
-
Leung, Ying Ying, Orbai, Ana-Maria, Ogdie, Alexis, Coates, Laura C., de Wit, Maarten, Callis Duffin, Kristina, Eder, Lihi, Gladman, Dafna D., Goel, Niti, Mease, Philip J., Strand, Vibeke, FitzGerald, Oliver, and Tillett, William
- Abstract
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Working Group reported at the 2018 GRAPPA annual meeting on the outcome of the OMERACT 2018 Conference in Terrigal, Australia. The working group presented the endorsement of the 66/68 joint count for the assessment of peripheral arthritis and the provisional endorsement of the PsA Impact of Disease 12 questionnaire for the assessment of PsA-specific health-related quality of life in PsA randomized controlled trials and observational studies. In this report, the group presents its plan to seek OMERACT endorsement for outcome measures that address the domains of MSK disease activity for enthesitis and dactylitis, physical function, fatigue, and structural damage following the OMERACT Filter 2.1 methodology.
- Published
- 2019
- Full Text
- View/download PDF
15. Prologue: 2019 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
- Author
-
Callis Duffin, Kristina, Gladman, Dafna D., Goel, Niti, and Gottlieb, Alice B.
- Abstract
The 2019 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held in Paris, France, and was attended by rheumatologists, dermatologists, representatives of biopharmaceutical companies, and patients. As in previous years, GRAPPA members held a symposium for trainees to discuss their research in psoriatic disease with experts in the field. Other subjects featured during the annual meeting included a composites workshop to review continuous composite measures; the GRAPPA-Collaborative Research Network’s third annual meeting; the need for a precision medicine approach to the treatment of psoriatic disease; updates from working groups in International Dermatology Outcome Measures and Outcome Measures in Rheumatology; a debate on the effectiveness of methotrexate in the treatment of psoriatic arthritis (PsA); updating recommendations for optimal treatment approaches for patients with PsA; an update on GRAPPA’s research and educational projects; and the GRAPPA ultrasound (US) working group’s goal to optimize the evaluation of enthesitis in patients with PsA using US through the development of a diagnostic US enthesitis tool. In this Prologue, we introduce the papers that summarize that meeting.
- Published
- 2020
- Full Text
- View/download PDF
16. Prologue: 2018 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
- Author
-
Duffin, Kristina Callis, Gladman, Dafna D., Gottlieb, Alice B., and Goel, Niti
- Subjects
PSORIATIC arthritis ,PSORIASIS ,RHEUMATOLOGISTS ,MEDICAL research ,HEALTH outcome assessment - Abstract
The 2018 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held in Toronto, Ontario, Canada, and was attended by rheumatologists, dermatologists, and representatives of biopharmaceutical companies and patients. As in previous years, GRAPPA members held a symposium for trainees to discuss their research in psoriatic disease with experts in the field. Other subjects featured during the annual meeting included GRAPPA-Collaborative Research Network's second annual meeting; the association between psoriatic disease and cardiovascular events; updates from working groups in International Dermatology Outcome Measures (IDEOM) and Outcome Measures in Rheumatology (OMERACT); a 2016 study that benchmarked care in psoriatic arthritis (PsA); the genetic contribution to PsA and strong need for genome-wide association studies on patients with PsA; the GRAPPA Ultrasound Working Group's goal to optimize the evaluation of enthesitis in patients with PsA using ultrasound through the development and validation of new instruments; and an update on GRAPPA's research and educational projects. In this prologue, we introduce the papers that summarize the meeting. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Proceedings of the 2017 GRAPPA Collaborative Research Network Meeting
- Author
-
Jadon, Deepak R., Chandran, Vinod, Stober, Carmel, Ogdie, Alexis, Armstrong, April W., Callis Duffin, Kristina, Gladman, Dafna D., Helliwell, Philip S., O’Sullivan, Denis, de Wit, Maarten, FitzGerald, Oliver, and Ritchlin, Christopher T.
- Abstract
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Collaborative Research Network (CRN) is an endeavor that aims to address gaps in the knowledge of the etiopathogenesis and management of psoriatic disease by best using the large community of experienced investigators who are already collecting rich clinical phenotype data and biologic samples using validated techniques. Exemplar rheumatology and dermatology projects will inform strategies to implement the CRN, while input and funding from government organizations, charities, and industry will shape the CRN. The key immediate priorities to establish the CRN are discussed herein and include (1) strategies for building infrastructure to collect and store biosamples and associated clinical data, (2) best practices for sample collection and storage, (3) approaches to engage the GRAPPA community of investigators and industry to collaborate most effectively on shared priorities, and (4) agreement on a funding strategy. The following 4 CRN candidate flagship research areas were identified: (1) predictors of treatment response in psoriatic arthritis (PsA) and cutaneous psoriasis (PsC) to permit personalized and stratified medicine approaches; (2) predictors of structural damage and disease severity, linking with the existing PsA BioDAM project; (3) predictors of PsC progressing to PsA to enable earlier intervention and possibly halt progression to PsA; and (4) comorbidity prevalence and effect on clinical outcomes in psoriatic disease. The collaboration and momentum provided by a GRAPPA-CRN will offer more than the sum of its individual contributing centers. A CRN will permit high-quality research that can more effectively address questions pertinent to patients, clinicians, scientists, industry, and governments.
- Published
- 2018
- Full Text
- View/download PDF
18. The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database
- Author
-
Gladman, Dafna D., Coates, Laura C., Jadon, Deepak R., Tillett, William, Mease, Philip J., and Vis, Marijn
- Abstract
The members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) have shown great interest in developing a common GRAPPA database. To address this interest, GRAPPA included a symposium at its 2017 annual meeting to examine the concepts of registries and databases. At this symposium, examples of existing databases were reviewed, and their challenges and achievements were discussed.
- Published
- 2018
- Full Text
- View/download PDF
19. Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting
- Author
-
Holland, Richard, Tillett, William, Ogdie, Alexis, Leung, Ying Y., Gladman, Dafna D., Callis Duffin, Kristina, Coates, Laura C., Mease, Philip J., Eder, Lihi, Strand, Vibeke, Elmamoun, Musaab, Højgaard, Pil, Chau, Jeffrey, de Wit, Maarten, Goel, Niti, Lindsay, Chris A., FitzGerald, Oliver, Shea, Bev, Beaton, Dorcas, and Orbai, Ana-Maria
- Abstract
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)–Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Core Set working group is in the process of selecting core instruments for PsA clinical trials. During a 2-h workshop and breakout group discussions at the GRAPPA 2017 annual meeting in Amsterdam, the Netherlands, participants discussed the first set of candidate instruments to be taken through the OMERACT Filter 2.1 instrument selection process: 66/68 swollen/tender joint count (66/68JC), Spondyloarthritis Consortium of Canada (SPARCC) enthesitis index, patient’s global assessment (GRAPPA and OMERACT formulations), Health Assessment Questionnaire–Disability Index (HAQ-DI), Psoriatic Arthritis Impact of Disease (PsAID) questionnaires 9 and 12, and Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue. Based on the assessment of domain match (content and face validity) and feasibility according to the OMERACT instrument selection criteria, the working group recommends continuing with appraisal of construct validity and discrimination for 66/68JC, SPARCC, PsAID 9 and 12, HAQ-DI, and FACIT-Fatigue. In addition, it recommends repeating the OMERACT Filter 2.1 process for patient global instruments because of insufficient votes. Additional sets of candidate instruments for the PsA core instrument set will be evaluated in a similar process.
- Published
- 2018
- Full Text
- View/download PDF
20. Prologue: 2018 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
- Author
-
Callis Duffin, Kristina, Gladman, Dafna D., Gottlieb, Alice B., and Goel, Niti
- Abstract
The 2018 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held in Toronto, Ontario, Canada, and was attended by rheumatologists, dermatologists, and representatives of biopharmaceutical companies and patients. As in previous years, GRAPPA members held a symposium for trainees to discuss their research in psoriatic disease with experts in the field. Other subjects featured during the annual meeting included GRAPPA-Collaborative Research Network’s second annual meeting; the association between psoriatic disease and cardiovascular events; updates from working groups in International Dermatology Outcome Measures (IDEOM) and Outcome Measures in Rheumatology (OMERACT); a 2016 study that benchmarked care in psoriatic arthritis (PsA); the genetic contribution to PsA and strong need for genome-wide association studies on patients with PsA; the GRAPPA Ultrasound Working Group’s goal to optimize the evaluation of enthesitis in patients with PsA using ultrasound through the development and validation of new instruments; and an update on GRAPPA’s research and educational projects. In this prologue, we introduce the papers that summarize the meeting.
- Published
- 2019
- Full Text
- View/download PDF
21. Prologue: 2017 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
- Author
-
Helliwell, Philip S., Gladman, Dafna D., and Gottlieb, Alice B.
- Abstract
The 2017 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held in Amsterdam, the Netherlands, and was attended by rheumatologists, dermatologists, representatives of biopharmaceutical companies, and patients. As in previous years, GRAPPA members held a symposium for trainees to discuss their research in psoriatic disease with experts in the field. Other subjects featured during the annual meeting included a discussion of the history, clinical features, controversies, and immunogenetics of juvenile psoriatic arthritis; updates from working groups in Outcome Measures in Rheumatology and International Dermatology Outcome Measures; a discussion of the benefits and challenges of setting up a longitudinal psoriatic arthritis (PsA) database; 3 separate discussions of the effects of the microbiome on skin and joints in psoriasis and PsA; a discussion of options for assessing joints and entheses in PsA by ultrasonography and magnetic resonance imaging; an update on GRAPPA’s research and educational projects; a discussion of patient centricity, including the incorporation of patient research partners (PRP) into psoriasis and PsA research and educational efforts, from GRAPPA’s PRP; and a discussion of the GRAPPA-Collaborative Research Network’s inaugural meeting. In this prologue, we introduce the papers that summarize that meeting.
- Published
- 2018
- Full Text
- View/download PDF
22. Future trends in research in psoriatic arthritis.
- Author
-
Gladman, Dafna D
- Abstract
Major advances have taken place in the study of psoriatic arthritis (PsA) in the past several decades. Future trends in research will likely be based on these advances and will span a wide spectrum of activities including further refinement of disease definition and particularly disease pattern. More precise definitions for axial and peripheral disease and in particular arthritis mutilans will be necessary for further genetic and biomarker studies. Early definition of PsA is crucial. Future research will concentrate on identifying genetic and other biomarkers for early diagnosis, disease expression, disease progression, and comorbidities. Newer therapies will be developed as well.
- Published
- 2012
- Full Text
- View/download PDF
23. Toward Treating to Target in Psoriatic Arthritis
- Author
-
Gladman, Dafna D.
- Abstract
The concept “treat to target” in rheumatology was first developed for rheumatoid arthritis. A similar attempt to develop such an approach for spondyloarthritis was unsuccessful because the assessment tools and target of therapy had not been developed. In psoriatic arthritis (PsA), composite indices to assess disease activity, disease state, and responsiveness have been developed and can be used as targets. There are a number of definitions for remission, but none are widely accepted. However, a state of minimal disease activity has been defined. There is evidence now that the treat-to-target approach is feasible, using the minimal disease activity state as a target and devising a tight control approach, which is superior to standard of care. Further work will determine the best target and the best approach to reach it.
- Published
- 2015
- Full Text
- View/download PDF
24. Second update on psoriatic disease. Foreword.
- Author
-
Moll, John M H and Gladman, Dafna D
- Published
- 2012
- Full Text
- View/download PDF
25. Psoriatic arthritis from Wright's era until today.
- Author
-
Gladman, Dafna D
- Abstract
This article reviews advances related to psoriatic arthritis (PsA). While the period since Wright's seminal papers is emphasized, his achievements are reviewed in light of knowledge of PsA in his day, as well as knowledge gained since the seminal work of Wright and Moll. Since other presentations focus on pathogenesis and treatment, this article emphasizes the clinical features and prognosis, as well as development of outcome measures.
- Published
- 2009
- Full Text
- View/download PDF
26. Longitudinal cohort studies.
- Author
-
Gladman DD and Farewell VT
- Subjects
- Adult, Canada, Databases, Factual, Female, Hospitals, University, Humans, Male, Middle Aged, Prognosis, Arthritis, Psoriatic, Longitudinal Studies
- Abstract
Rheumatological disorders are complex conditions characterized by a variety of clinical manifestations and courses in different patients with the same condition. The best way to understand the course and prognosis of these patients is through longitudinal observational cohort studies. Such studies have been facilitated by computer technology that allows tracking of large numbers of patients and visits and analysis of a large amount of data. There are requirements for such datasets to be informative: internal and external consistency; clearly defined methods of observation and measurement; complete followup; consideration of potential confounders. We describe the usefulness of an observational cohort analysis using the University of Toronto Psoriatic Arthritis Clinic Database as a model. Analysis issues are highlighted and proposed mechanisms offered for keeping patients involved to ensure complete followup is maintained.
- Published
- 2005
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.